Akari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Price Performance

Shares of AKTX opened at $1.19 on Wednesday. Akari Therapeutics has a twelve month low of $1.08 and a twelve month high of $5.50. The company’s fifty day simple moving average is $1.82 and its 200-day simple moving average is $2.63.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Akari Therapeutics stock. Omnia Family Wealth LLC increased its stake in Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 87,628 shares of the biopharmaceutical company’s stock after buying an additional 28,511 shares during the period. Omnia Family Wealth LLC owned 1.55% of Akari Therapeutics worth $273,000 as of its most recent SEC filing. Institutional investors own 5.06% of the company’s stock.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.